RE:RE:RE:RE:RE:ENDPWith a gaap loss of $11.18 per share they may not need to cover. If these guys are starting to write down assets they paid a premium for, we have to remember they still have the debt that needs to be paid from when they purchased them. The price hikes they put on some of these drugs will make it more attractive for competition to jump in and there may be more to come.
subwave wrote: ...and it will be fun to see how this millions of short shares will be covered.